1. ZHAW digitalcollection
  2. Gesundheit
  3. Publikationen
  4. Publikationen Gesundheit
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSandmann, Frank G.-
dc.contributor.authorMostardt, Sarah-
dc.contributor.authorLhachimi, Stefan K.-
dc.contributor.authorGerber-Grote, Andreas-
dc.date.accessioned2018-12-07T13:31:50Z-
dc.date.available2018-12-07T13:31:50Z-
dc.date.issued2018-
dc.identifier.issn1473-7167de_CH
dc.identifier.issn1744-8379de_CH
dc.identifier.issn1744-8379de_CH
dc.identifier.urihttps://digitalcollection.zhaw.ch/handle/11475/13669-
dc.description.abstractThe efficiency-frontier approach (EFA) to health economic evaluation aims to benchmark the relative efficiency of new drugs with the incremental cost-effectiveness ratios (ICERs) of non-dominated comparators. By explicitly considering any differences in health outcomes and costs, it enhances the internal reference pricing (IRP) policy that was officially endorsed by Germany as the first country worldwide in 1989. However, the EFA has been repeatedly criticized since its official endorsement in 2009. Areas covered: This perspective aims to stimulate the debate by discussing whether the main objections to the EFA are technically valid, irrespective of national contextual factors in Germany with reservations towards using cost-per-quality-adjusted life year (QALY) thresholds. Moreover, we comparatively assessed whether the objections are truly unique to the EFA or apply equally to IRP and cost-effectiveness thresholds. Expert commentary: The plethora of objections to the EFA (n = 20) has obscured that many objections are neither technically valid nor unique to the EFA. Compared with cost-effectiveness thresholds, only two objections apply uniquely to the EFA and concern intended key properties: (1) no external thresholds are needed and (2) the EFA is sensitive to price changes of comparators. Combining these policies and developing them further are under-utilized research areas.de_CH
dc.language.isoende_CH
dc.publisherTaylor & Francisde_CH
dc.relation.ispartofExpert Review of Pharmacoeconomics & Outcomes Researchde_CH
dc.rightsLicence according to publishing contractde_CH
dc.subjectReference pricingde_CH
dc.subjectCost effectivenessde_CH
dc.subjectDecision makingde_CH
dc.subjectEconomic evaluationde_CH
dc.subjectHealth technology assessmentde_CH
dc.subjectBenchmarkingde_CH
dc.subjectCost-Benefit Analysisde_CH
dc.subjectDrug Costsde_CH
dc.subjectGermanyde_CH
dc.subjectHumansde_CH
dc.subjectOutcome Assessment (Health Care)de_CH
dc.subjectPharmaceutical Preparationsde_CH
dc.subjectTechnology Assessment, Biomedicalde_CH
dc.subjectEconomicsde_CH
dc.subjectQuality-Adjusted Life Yearsde_CH
dc.subjectMedicalde_CH
dc.subject.ddc362.1041: Gesundheitsökonomiede_CH
dc.titleThe efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing : combining the best of both worlds?de_CH
dc.typeBeitrag in wissenschaftlicher Zeitschriftde_CH
dcterms.typeTextde_CH
zhaw.departementGesundheitde_CH
dc.identifier.doi10.1080/14737167.2018.1497976de_CH
zhaw.funding.euNode_CH
zhaw.issue5de_CH
zhaw.originated.zhawYesde_CH
zhaw.pages.end486de_CH
zhaw.pages.start475de_CH
zhaw.publication.statuspublishedVersionde_CH
zhaw.volume18de_CH
zhaw.publication.reviewPeer review (Publikation)de_CH
Appears in collections:Publikationen Gesundheit

Files in This Item:
There are no files associated with this item.
Show simple item record
Sandmann, F. G., Mostardt, S., Lhachimi, S. K., & Gerber-Grote, A. (2018). The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing : combining the best of both worlds? Expert Review of Pharmacoeconomics & Outcomes Research, 18(5), 475–486. https://doi.org/10.1080/14737167.2018.1497976
Sandmann, F.G. et al. (2018) ‘The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing : combining the best of both worlds?’, Expert Review of Pharmacoeconomics & Outcomes Research, 18(5), pp. 475–486. Available at: https://doi.org/10.1080/14737167.2018.1497976.
F. G. Sandmann, S. Mostardt, S. K. Lhachimi, and A. Gerber-Grote, “The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing : combining the best of both worlds?,” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 18, no. 5, pp. 475–486, 2018, doi: 10.1080/14737167.2018.1497976.
SANDMANN, Frank G., Sarah MOSTARDT, Stefan K. LHACHIMI und Andreas GERBER-GROTE, 2018. The efficiency-frontier approach for health economic evaluation versus cost-effectiveness thresholds and internal reference pricing : combining the best of both worlds? Expert Review of Pharmacoeconomics & Outcomes Research. 2018. Bd. 18, Nr. 5, S. 475–486. DOI 10.1080/14737167.2018.1497976
Sandmann, Frank G., Sarah Mostardt, Stefan K. Lhachimi, and Andreas Gerber-Grote. 2018. “The Efficiency-Frontier Approach for Health Economic Evaluation versus Cost-Effectiveness Thresholds and Internal Reference Pricing : Combining the Best of Both Worlds?” Expert Review of Pharmacoeconomics & Outcomes Research 18 (5): 475–86. https://doi.org/10.1080/14737167.2018.1497976.
Sandmann, Frank G., et al. “The Efficiency-Frontier Approach for Health Economic Evaluation versus Cost-Effectiveness Thresholds and Internal Reference Pricing : Combining the Best of Both Worlds?” Expert Review of Pharmacoeconomics & Outcomes Research, vol. 18, no. 5, 2018, pp. 475–86, https://doi.org/10.1080/14737167.2018.1497976.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.